China is evolving beyond a single public reimbursement model toward a layered access system that combines national coverage, commercial funding, and early access programs. In 2025, these changes began to reshape how manufacturers think about pricing, evidence, and launch sequencing…
Latin American and MENA markets have long faced the challenge of balancing constrained public budgets with rising demand for newer therapies. In 2025, governments in these regions took concrete steps to modernize pricing rules, raise evidence expectations, expand partnership models,…
Across Europe, 2025 accelerated a shift from sequential regulatory and access steps to more connected process through the Joint Clinical Assessment. Regulatory approvals, and clinical portion of HTA evaluation are now more tightly linked, which has the potential to bring the evidence expectations closer together as well. In Trinity’s webinar ”Around…
Globally, 2025 marked a shift from debating drug pricing policy to implementing it. Pricing pressure intensified, evidence expectations rose, and long-standing access models began to change amid political and fiscal realities. In Trinity’s webinar “Around the World in Market Access…
Interventional cardiology continues to advance toward precision-based care, where treatment strategies are matched to patient characteristics and real-world outcomes guide decision-making. Coming out of TCT 2025, one of the leading interventional cardiology conferences, Trinity sees four trends shaping the next…
The Most Favored Nation (MFN) pricing policy is once again under consideration in the U.S. First put forward in a 2020 Executive Order (EO) by the Trump Administration, the 2025 MFN policy aims to eliminate global free riding by aligning…
The momentum behind AI-driven advancements in life sciences has never been stronger, and this trend was spotlighted in Everest Group’s new 2025 PEAK Matrix® report, “Life Sciences AI and Analytics Services for Commercial PEAK Matrix® Assessment 2025.” Trinity Life…
President Trump signed the “One Big Beautiful Bill Act” (OBBBA) into law on July 4, 2025. The OBBBA is projected to reduce federal health spending by an estimated $900 billion[1] over the next decade. Central to the legislation is…
In today’s fast-evolving digital landscape, life sciences companies face a critical challenge: reach the right healthcare professionals (HCPs) with the right message, through the right channels, at the right time. At Trinity Life Sciences, we’re proud to help our…
China’s pharmaceutical landscape is not only vast in scale but also rapidly evolving with an emphasis on balancing access with affordability. This year’s NRDL update stands out. The introduction of the value rating system continues to raise the…